Anika Therapeutics, Inc. (ANIK)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | 28,219 | 38,753 | 41,921 | |
| Cost of revenue | 13,856 | 37,313 | 14,556 | |
| Gross profit | 14,363 | 1,440 | 27,365 | |
| Long lived asset impairment | - | 3,101 | - | |
| Selling, general and administrative | 12,230 | 19,112 | 19,806 | |
| Research and development | 6,313 | 7,244 | 7,398 | |
| Total operating expenses | 18,543 | 29,457 | 27,204 | |
| Loss from operations | -4,180 | -28,017 | 161 | |
| Interest and other income (expense), net | 214 | 406 | 595 | |
| Loss before income taxes | -3,966 | -27,611 | 756 | |
| Provision for income taxes | 681 | 2,307 | 844 | |
| Loss from continuing operations | -4,647 | - | - | |
| Loss from discontinued operations, net of tax | 677 | - | - | |
| Net loss | -3,970 | -29,918 | -88 | |
| Foreign currency translation adjustment | 1,348 | 715 | -101 | |
| Comprehensive loss | -2,622 | -29,203 | -189 | |
| Basic (in shares) | 14,364,000 | 14,768,000 | 14,839,000 | |
| Diluted (in shares) | 14,517,000 | 14,768,000 | 14,839,000 | |
| Us-gaap_earningspersharebasic | -0.28 | -2.03 | -0.01 | |
| Us-gaap_earningspersharediluted | -0.28 | -2.03 | -0.01 | |